Back to Search
Start Over
Addressing steroid phobia: improving the risk-benefit ratio with new agents.
- Source :
-
Allergy and asthma proceedings [Allergy Asthma Proc] 2008 Jul-Aug; Vol. 29 (4), pp. 358-64. - Publication Year :
- 2008
-
Abstract
- Inhaled corticosteroids (ICSs) are the preferred first-line preventative therapy for asthma of all severity levels. Although these drugs have been proven efficacious, concerns of adverse systemic affects due to both long- and short-term use continue to limit patient compliance with dosing regimens. Deficits in bone growth, bone density, and hypothalamic-pituitary-adrenal axis function, in addition to cataract formation and elevated intraocular pressure/glaucoma, have been associated with ICS use in some studies. Although some of these studies were flawed, featured drugs that are less commonly prescribed today, or both, adverse effects from chronic ICSs use are still a cause of concern today. Current therapies are designed to be efficacious at minimal doses, limiting potential side effects, increasing adherence, and improving asthma control.
- Subjects :
- Administration, Inhalation
Adrenal Cortex Hormones administration & dosage
Anti-Asthmatic Agents administration & dosage
Body Height drug effects
Bone Density drug effects
Dose-Response Relationship, Drug
Eye drug effects
Humans
Hypothalamo-Hypophyseal System drug effects
Pituitary-Adrenal System drug effects
Risk Assessment
Treatment Outcome
Adrenal Cortex Hormones adverse effects
Anti-Asthmatic Agents adverse effects
Asthma drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1088-5412
- Volume :
- 29
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Allergy and asthma proceedings
- Publication Type :
- Academic Journal
- Accession number :
- 18702881
- Full Text :
- https://doi.org/10.2500/aap.2008.29.3132